CIPO Patents = 1

Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 99(Granted Patents)

Location History:

Cambridge, GB (2007)
Abingdon, GB (2009 - 2014)
Abington, GB (2010 - 2017)
Singapore, SG (2012 - 2019)
Great Abington, GB (2019 - 2022)

Company Filing History:

13 out of 262

Cancer Research Technology Limited

patents

11 out of 24

The Institute of Cancer Research

Vernalis (cambridge) Limited

The Institute of Cancer

patent

8. 1 out of 1

Institute of Cancer Research of Royal Cancer Hospital

patent

9. 1 out of 805

National University of Singapore

patents

10. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2022

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11234987 - Isoxazole compounds as inhibitors of heat shock proteins (2022-02-01),

2. 10413550 - Isoxazole compounds as inhibitors of heat shock proteins (2019-09-17),

3. 10308631 - Selective anti-cancer compounds (2019-06-04),

4. 9718793 - Isoxazole compounds as inhibitors of heat shock proteins (2017-08-01),

5. 9624242 - 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt (2017-04-18),

6. 9062074 - (9E)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt (2015-06-23),

7. 8987243 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt (2015-03-24),

8. 8980873 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt (2015-03-17),

9. 8642594 - Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors (2014-02-04),

10. 8507480 - Isoxazole compounds as inhibitors of heat shock proteins (2013-08-13),

11. 8487095 - Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms (2013-07-16),

12. 8450310 - Isoxazole compounds as inhibitors of heat shock proteins (2013-05-28),

13. 8163747 - Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms (2012-04-24),

14. 7820658 - Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors (2010-10-26),

15. 7803831 - 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer (2010-09-28),

Title: Innovations and Contributions of Brian William Dymock

Introduction: Brian William Dymock is a notable inventor based in Abingdon, GB, recognized for his significant contributions to the field of pharmaceuticals and cancer research. With a prolific portfolio of 20 patents, Dymock has focused on developing innovative compounds aimed at targeting heat shock proteins, which play a crucial role in cancer treatment.

Latest Patents: Among his recent patents, Dymock has developed isoxazole compounds that function as inhibitors of heat shock proteins, specifically targeting HSP90 activity. These isoxazoles are designed to treat various cancers and involve complex molecular structures. The patents detail compounds formulated with various aryl and heteroaryl radicals, divalent C-Calkylene, and other radical components, showcasing Dymock's expertise in medicinal chemistry and the molecular intricacies of drug design.

Career Highlights: Dymock has lent his expertise to prominent institutions, including Cancer Research Technology Limited and The Institute of Cancer Research. His role in these organizations has facilitated advancements in cancer therapeutics, solidifying his impact in the research community.

Collaborations: Throughout his career, Dymock has collaborated with notable colleagues such as Martin James Drysdale and Edward McDonald. These partnerships have been instrumental in driving innovative research initiatives and developing promising treatment options for cancer.

Conclusion: Brian William Dymock's innovative work in isoxazole compounds exemplifies the vital role of inventors in advancing medical science. His contributions to the field not only demonstrate his commitment to cancer research but also highlight the importance of collaboration in achieving significant breakthroughs. With a total of 20 patents to his name, Dymock continues to influence the landscape of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent (CIPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.